A Phase 3 interventional study of Menitorix™ and Infanrix™ penta in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 8 sites in Spain. Open to participants aged 8 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-27.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 50th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2007, is one of 48 in phase 3, and was the 37th registered.
176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.
Browse Haemophilus Infections studies →None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →
Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 8 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 313 is below the median of 458 across 163 interventional studies indexed under Haemophilus Infections.
Median enrollment 445 across the 80 interventional studies, 270 across the 2 observational. Of the 81 that completed or were terminated, 55 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase IIIb study is to evaluate the immunogenicity, reactogenicity \& safety of GSK Biologicals' Hib-MenC vaccine (Menitorix™) when co-administered with GSK Biologicals' DTPa-HBV-IPV vaccine (Infanrix™ penta) \& Wyeth's 7-valent pneumococcal conjugate vaccine (Prevenar™) in preterm infants as a 3-dose primary vaccination course during the first 6 months of life (at 2, 4, 6 months of age) and of a booster dose of Menitorix™ when co-administered with GSK Biologicals' DTPa-IPV vaccine (Infanrix IPV) and Wyeth's Prevenar in the second year of life (16-18 months of age). The control is a group of full-term infants receiving the same vaccines. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
This multicenter study is open \& consists of a primary \& a booster phase. The study has 2 treatment groups (Preterm \& Full-term) that will receive the same vaccinations; the Full-term group will be the active control. Four blood samples will be collected from all subjects for immunogenicity analyses; 2 in the primary phase at prior to the first vaccination and one month after the third vaccination and 2 in the booster phase at prior to booster dose and one month after booster dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects must satisfy the following criteria at study entry:
All preterm subjects must satisfy the following criteria at study entry:
All full-term subjects must satisfy the following criteria at study entry:
Exclusion Criteria:
Specific criteria for the booster part of the study (to be checked at Visit 5, study month 14):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
Biological: Menitorix™ · Biological: Infanrix™ penta · Biological: Prevenar™ · Biological: Infanrix™ IPV
Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
Biological: Menitorix™ · Biological: Infanrix™ penta · Biological: Prevenar™ · Biological: Infanrix™ IPV
Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
Intramuscular injection, 3 doses in the primary study
Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
Intramuscular injection, 1 dose in the Booster study.
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)
Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of protection.
Time frame: One month after the third vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:8
rSBA-MenC titer greater than or equal to 1:8 is indicative of protection.
Time frame: One month after the third vaccination
Number of Subjects With Anti-Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to the Cut-off Values
Anti-PRP antibody cut-off values assessed include 0.15 micrograms per milliliter (µg/mL) and 1 µg/mL.
Time frame: Before vaccination (at Day 0)
Number of Subject With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1 Microgram Per Milliliter
Anti-PRP antibody cut-off value assessed include 1 microgram per milliliter (µg/mL).
Time frame: One month after the third vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values
rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.
Time frame: Before vaccination (at Day 0)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values
rSBA-MenC titer cut-off values assessed include 1:32 and 1:128.
Time frame: One month after the third vaccination
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.
Time frame: Before vaccination (at Day 0)
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.
Time frame: One month after the third dose
Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.
Time frame: Before vaccination (at Day 0)
Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.
Time frame: One month after the third dose
Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration
Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).
Time frame: Before vaccination (at Day 0)
Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration
Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).
Time frame: One month after the third dose
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration
Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).
Time frame: Before vaccination (at Day 0)
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration
Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).
Time frame: One month after the third dose
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer
rSBA-MenC titers are given as geometric mean titers (GMTs).
Time frame: Before vaccination (at Day 0)
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer
rSBA-MenC titers are given as geometric mean titers (GMTs).
Time frame: One month after the third dose
Number of Subjects Reporting Solicited Local Symptoms
Solicited local symptoms assessed include pain, redness and swelling and are presented across doses.
Time frame: During the 4-day follow-up period after any primary vaccination dose
Number of Subjects Reporting Solicited General Symptoms
Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite and are presented across doses.
Time frame: During the 4-day follow-up period after any primary vaccination dose
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: Within 31 days after each primary vaccination
Number of Subjects Reporting Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: Throughout the entire primary vaccination phase
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Migrogram Per Milliliter (µg/mL)
Anti-PRP antibody cut-off value assessed was 0.15 migrogram per milliliter (µg/mL).
Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1.0 Migrogram Per Milliliter (µg/mL)
Anti-PRP antibody cut-off value assessed was 1.0 migrogram per milliliter (µg/mL).
Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values
rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.
Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to the Cut-off Values
Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2.0 µg/mL.
Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)
Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to the Cut-off Values
Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL. Note: the protocol planned an analysis on HBs after the booster dose, but this analysis was not performed as the vaccines administered as booster doses did not contain HBs component.
Time frame: Prior to (Month 14) the booster vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration
Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) in micrograms per milliliter (µg/mL).
Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration
Anti-HBs concentrations are given as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). Note: Planned analysis in the protocol of HBs after the booster dose was not performed as booster vaccines did not contain HBs component.
Time frame: Prior to (Month 14) the booster vaccination
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer
rSBA-MenC titers are given as geometric mean titers (GMTs).
Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)
Number of Subjects Reporting Solicited Symptoms (Local and General)
Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite.
Time frame: During the 4-day follow-up period following booster vaccination
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: Within 31 days after the booster vaccination (month 15)
Number of Subjects Reporting Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Period 1 is defined as 31 days after last primary vaccination until administration of booster dose (Month 14). Period 2 is defined as the administration of the booster dose until the end of the study (Month 15).
Time frame: 31 days after last primary vaccination until administration of booster dose (Month 14) and from the administration of the booster dose until the end of the study (Month 15)
| Milestone | Preterm Group | Full-term Group |
|---|---|---|
| Started | 163 | 150 |
| Completed | 162 | 147 |
| Not completed | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | Preterm Group | Full-term Group |
|---|---|---|
| Started | 154 | 144 |
| Completed | 151 | 143 |
| Not completed | 3 | 1 |
| Withdrew: Lost to follow-up | 3 | 1 |
Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of protection.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) | 139 | 141 |
rSBA-MenC titer greater than or equal to 1:8 is indicative of protection.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:8 | 142 | 140 |
Anti-PRP antibody cut-off values assessed include 0.15 micrograms per milliliter (µg/mL) and 1 µg/mL.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 0.15 µg/mL | 38 | 43 |
| ≥ 1.0 µg/mL | 5 | 9 |
Anti-PRP antibody cut-off value assessed include 1 microgram per milliliter (µg/mL).
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Number of Subject With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1 Microgram Per Milliliter | 133 | 134 |
rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 1:8 | 16 | 23 |
| ≥ 1:32 | 5 | 11 |
| ≥ 1:128 | 0 | 3 |
rSBA-MenC titer cut-off values assessed include 1:32 and 1:128.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 1:32 | 142 | 139 |
| ≥ 1:128 | 135 | 136 |
Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 0.3 µg/mL | 23 | 36 |
| ≥ 2.0 µg/mL | 3 | 8 |
Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 0.3 µg/mL | 140 | 141 |
| ≥ 2.0 µg/mL | 127 | 136 |
Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 10 mIU/mL | 89 | 78 |
| ≥ 100 mIU/mL | 3 | 8 |
Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 10 mIU/mL | 128 | 129 |
| ≥ 100 mIU/mL | 109 | 117 |
Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).
| micrograms per milliliter (µg/mL) | Preterm Group | Full-term Group |
|---|---|---|
| Anti-PRP (n=140, 138) | 0.116 (0.101 to 0.133) | 0.140 (0.117 to 0.167) |
| Anti-PSC (n=142, 137) | 0.19 (0.17 to 0.22) | 0.25 (0.21 to 0.30) |
Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).
| micrograms per milliliter (µg/mL) | Preterm Group | Full-term Group |
|---|---|---|
| Anti-PRP (n= 140, 142) | 10.437 (8.398 to 12.970) | 10.473 (8.547 to 12.833) |
| Anti-PSC (n= 140, 141) | 6.34 (5.57 to 7.22) | 7.46 (6.67 to 8.34) |
Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Preterm Group | Full-term Group |
|---|---|---|
| Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration | 24.79 (19.82 to 31.00) | 16.67 (13.52 to 20.56) |
Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Preterm Group | Full-term Group |
|---|---|---|
| Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration | 372.30 (299.98 to 462.04) | 586.58 (473.80 to 726.21) |
rSBA-MenC titers are given as geometric mean titers (GMTs).
| Titer | Preterm Group | Full-term Group |
|---|---|---|
| Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer | 4.9 (4.5 to 5.5) | 5.9 (4.9 to 6.9) |
rSBA-MenC titers are given as geometric mean titers (GMTs).
| Titer | Preterm Group | Full-term Group |
|---|---|---|
| Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer | 1055.9 (859.1 to 1297.7) | 1346.2 (1130.4 to 1603.1) |
Solicited local symptoms assessed include pain, redness and swelling and are presented across doses.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Pain | 106 | 100 |
| Redness | 94 | 123 |
| Swelling | 91 | 113 |
Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite and are presented across doses.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Drowsiness | 111 | 102 |
| Fever | 89 | 85 |
| Irritability/fussiness | 128 | 105 |
| Loss of appetite | 99 | 100 |
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Number of Subjects Reporting Unsolicited Adverse Events (AEs) | 56 | 72 |
SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAEs) | 11 | 8 |
Anti-PRP antibody cut-off value assessed was 0.15 migrogram per milliliter (µg/mL).
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Pre-booster (n= 133; 130) | 116 | 117 |
| Post-booster (n= 132; 134) | 132 | 134 |
Anti-PRP antibody cut-off value assessed was 1.0 migrogram per milliliter (µg/mL).
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Pre-booster (n= 133; 130) | 53 | 53 |
| Post-booster (n= 132; 134) | 132 | 134 |
rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 1:8 pre-booster (n= 134; 134) | 102 | 117 |
| ≥ 1:8 post-booster (n= 133; 137) | 132 | 136 |
| ≥ 1:32 pre-booster (n= 134; 134) | 95 | 115 |
| ≥ 1:32 post-booster (n= 133; 137) | 132 | 136 |
| ≥ 1:128 pre-booster (n= 134; 134) | 69 | 85 |
| ≥ 1:128 post-booster (n= 133; 137) | 131 | 136 |
Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2.0 µg/mL.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 0.3 µg/mL pre-booster (n= 130; 127) | 74 | 92 |
| ≥ 0.3 µg/mL post-booster (n= 117; 129) | 116 | 129 |
| ≥ 2.0 µg/mL pre-booster (n= 130; 127) | 11 | 11 |
| ≥ 2.0 µg/mL post-booster (n= 117; 129) | 105 | 124 |
Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL. Note: the protocol planned an analysis on HBs after the booster dose, but this analysis was not performed as the vaccines administered as booster doses did not contain HBs component.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| ≥ 10 mIU/mL pre-booster | 121 | 113 |
| ≥ 100 mIU/mL pre-booster | 61 | 71 |
Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) in micrograms per milliliter (µg/mL).
| micrograms per milliliter (µg/mL) | Preterm Group | Full-term Group |
|---|---|---|
| anti-PRP pre-booster (n= 133; 130) | 0.706 (0.565 to 0.881) | 0.777 (0.622 to 0.972) |
| anti-PRP post-booster (n= 132; 134) | 50.343 (41.627 to 60.884) | 54.625 (45.325 to 65.834) |
| anti-PSC pre-booster (n= 130; 127) | 0.42 (0.35 to 0.51) | 0.56 (0.47 to 0.67) |
| anti-PSC post-booster (n= 117; 129) | 10.06 (8.14 to 12.45) | 11.31 (9.60 to 13.31) |
Anti-HBs concentrations are given as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). Note: Planned analysis in the protocol of HBs after the booster dose was not performed as booster vaccines did not contain HBs component.
| mIU/mL | Preterm Group | Full-term Group |
|---|---|---|
| Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration | 95.9 (75.6 to 121.5) | 145.6 (112.1 to 189.1) |
rSBA-MenC titers are given as geometric mean titers (GMTs).
| titer | Preterm Group | Full-term Group |
|---|---|---|
| Pre-booster (n= 134; 134) | 79.3 (56.3 to 111.8) | 147.8 (110.9 to 197.1) |
| Post-booster (n= 133; 137) | 4883.1 (3783.1 to 6302.9) | 5288.8 (4244.9 to 6589.4) |
Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Pain | 82 | 98 |
| Redness | 77 | 109 |
| Swelling | 67 | 94 |
| Drowsiness | 33 | 46 |
| Fever | 43 | 53 |
| Irritability | 70 | 69 |
| Loss of appetite | 34 | 50 |
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Number of Subjects Reporting Unsolicited Adverse Events (AEs) | 34 | 42 |
SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Period 1 is defined as 31 days after last primary vaccination until administration of booster dose (Month 14). Period 2 is defined as the administration of the booster dose until the end of the study (Month 15).
| subjects | Preterm Group | Full-term Group |
|---|---|---|
| Period 1 | 10 | 2 |
| Period 2 | 1 | 0 |
Collected over For SAEs: the whole study period (Day 0 - Month 15); For frequent adverse events: solicited adverse events a 4-day period after vaccination, unsolicited adverse events a 31-day period after vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Preterm Group | — | 22/163 (13.5%) | 153/163 (93.9%) |
| Full-term Group | — | 10/150 (6.7%) | 144/150 (96%) |
| Event | Preterm Group | Full-term Group |
|---|---|---|
| BronchiolitisInfections and infestations | 6/163 | 2/150 |
| PneumoniaInfections and infestations | 4/163 | 1/150 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 4/163 | 0/150 |
| Upper respiratory tract infectionInfections and infestations | 3/163 | 0/150 |
| Gastroenteritis rotavirusInfections and infestations | 0/163 | 2/150 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 1/163 | 1/150 |
| GastroenteritisInfections and infestations | 1/163 | 1/150 |
| Lower respiratory tract infectionInfections and infestations | 1/163 | 1/150 |
| Meningococcal sepsisInfections and infestations | 0/163 | 1/150 |
| OsteomyelitisInfections and infestations | 0/163 | 1/150 |
| Event | Preterm Group | Full-term Group |
|---|---|---|
| RednessGeneral disorders | 94/163 | 123/150 |
| Irritability/fussinessGeneral disorders | 128/163 | 105/150 |
| RednessGeneral disorders | 77/154 | 109/144 |
| SwellingGeneral disorders | 91/163 | 113/150 |
| DrowsinessGeneral disorders | 111/163 | 102/150 |
| PainGeneral disorders | 82/154 | 98/144 |
| PainGeneral disorders | 106/163 | 100/150 |
| Loss of appetiteGeneral disorders | 99/163 | 100/150 |
| SwellingGeneral disorders | 67/154 | 94/144 |
| FeverGeneral disorders | 89/163 | 85/150 |
| Age, Continuous(weeks) | Preterm Group | Full-term Group | Total |
|---|---|---|---|
| Mean | 8.9 ± 1.15 | 8.8 ± 0.79 | 8.9 ± 0.99 |
| Sex: Female, Male(Participants) | Preterm Group | Full-term Group | Total |
|---|---|---|---|
| Female | 77 | 65 | 142 |
| Male | 86 | 85 | 171 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pediarix · Heptavalent Pneumococcal Conjugate Vaccine